PO-41 - Rivaroxaban is effective therapy for high risk cancer patients with venous thromboembolic disease.
about
Retrospective comparison of low molecular weight heparin vs. warfarin vs. oral Xa inhibitors for the prevention of recurrent venous thromboembolism in oncology patients: The Re-CLOT study.Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins.Evidence Gaps in the Era of Non-Vitamin K Oral Anticoagulants.
P2860
PO-41 - Rivaroxaban is effective therapy for high risk cancer patients with venous thromboembolic disease.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
PO-41 - Rivaroxaban is effecti ...... venous thromboembolic disease.
@en
type
label
PO-41 - Rivaroxaban is effecti ...... venous thromboembolic disease.
@en
prefLabel
PO-41 - Rivaroxaban is effecti ...... venous thromboembolic disease.
@en
P2093
P1433
P1476
PO-41 - Rivaroxaban is effecti ...... venous thromboembolic disease.
@en
P2093
I A Theberge
J C Bowdridge
M A Forgie
P304
P356
10.1016/S0049-3848(16)30174-8
P478
140 Suppl 1
P577
2016-04-08T00:00:00Z